SARS-CoV-2-induced remission of advanced classical Hodgkin lymphoma

Kurlapski, Michał; Romanowicz, Grzegorz; Taszner, Michał; Zaucha, Jan Maciej

doi:10.20452/pamw.16266

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Influenza requires hemagglutinin 3 and neuraminidase for host cell invasion, whereas SARS-CoV-2 relies on protein S. Both viruses depend on a viral RNA polymerase to express their proteins. Given that several clinical cases have been reported where in COVID-19 infections were associated with tumor regression in melanoma 4 and Hodgkin Lymphoma 5, 6 , we hypothesized that a host response to intratumoral injection of chemically inactivated SARS-CoV-2 may produce an anti-tumor effect in mouse models akin to what we observed with influenza. In this study our findings propose that inactivated SARS-CoV-2 vaccines may have the potential for use as a cancer immunotherapy.…”

Section: Introductionmentioning

confidence: 74%

“…where in COVID-19 infections were associated with tumor regression in melanoma 4 and Hodgkin Lymphoma 5,6 , we hypothesized that a host response to intratumoral injection of chemically inactivated SARS-CoV-2 may produce an anti-tumor effect in mouse models akin to what we observed with influenza. In this study our findings propose that inactivated SARS-CoV-2 vaccines may have the potential for use as a cancer immunotherapy.…”

Section: Introductionmentioning

confidence: 81%

See 1 more Smart Citation

Inactivated SARS-CoV-2 Reprograms the Tumor Immune Microenvironment and Improves Murine Cancer Outcomes

Giurini

Williams

Morin

et al. 2022

Preprint

View full text Add to dashboard Cite

Following the breakthrough of immune check point inhibitors (ICIs), a new era of immuno-oncology agents has emerged and established immunotherapy as a part of cancer treatment. Despite the improving outcomes of ICIs, many patients with initial response are known to develop acquired resistance later. There is increasing interest in utilizing other stimulatory means, such as anti-pathogen immune responses to induce anti-tumor immune responses. The immunostimulatory effects of anti-pathogen-treated tumors in combinations with ICI are known to potentially amplify anti-tumor immunity resulting in increased tumor responses and improved outcomes. Anti-pathogen-treated tumors can become immune-infiltrated “hot” tumors and demonstrate higher treatment response rates and improved survival. Our research group has previously demonstrated that tumors can be converted from “cold” to “hot” by intratumoral injection of a commercially available seasonal influenza vaccine. In continuation with our work, in deciphering the role of anti-viral immunity in the context of tumor immunology, we studied the role of inactivated SARS-CoV-2 virus as anti-tumor agent. Here we report that intratumoral injections of inactivated SARS-CoV-2 convert the immunologically cold tumors to hot by generating anti-tumor-mediated CD8+ T cells. Our findings suggest that inactivated SARS-CoV-2 can be used as an immune modulator in immunotherapy for melanoma and triple-negative breast cancer.

show abstract

Section: Introductionmentioning

confidence: 74%

Section: Introductionmentioning

confidence: 81%

Inactivated SARS-CoV-2 Reprograms the Tumor Immune Microenvironment and Improves Murine Cancer Outcomes

Giurini

Williams

Morin

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…However, recent reports have demonstrated that the imaging and serological symptoms of certain cancer patients were relieved after SARS-CoV-2 infection ( 8 ). This effect of SARS-CoV-2 infection occurs not only in hematological malignancies, such as Epstein-Barr virus-positive classical Hodgkin lymphoma ( 9 ), follicular lymphoma ( 10 ), acute myeloid leukemia ( 11 ) and chronic lymphocytic leukemia ( 12 ), but also in solid tumors such as colon cancer ( 13 , 14 ) and renal cell carcinoma ( 15 ). Although the underlying mechanism has not been entirely understood, researchers have speculated that SARS-CoV-2 can activate the body's innate immunity.…”

Section: Discussionmentioning

confidence: 99%

Tumor reduction after SARS‑CoV‑2 infection in a patient with lung cancer: A case report

Zhang,

Chen,

Sun

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Lung cancer is one of the most common malignancies worldwide. Since the global outbreak of the coronavirus disease 2019 (COVID-19) pandemic in 2020, the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on lung cancer has been extensively studied. Despite reports about SARS-CoV-2 infection inducing a significant increase in the number of medical visits for patients with cancer, the virus has also been reported to produce some unknown benefits. The present study reports the case of a patient with lung cancer whose tumor lesion was reduced in size after SARS-CoV-2 infection even though the therapeutic regimen remained unchanged. Although the mechanism involved is not yet understood, this case supports the novel idea of applying SARS-CoV-2 in oncolytic virotherapy.

show abstract

“…It has been observed in a number of cancer types. RT can increase the immunogenicity of a tumor and therefore could be used to improve IO effectiveness, or vice versa ( 14 ). To stimulate AE, it is necessary to stimulate the recruitment and activation of antitumor cells, including CTLs and NK cells.…”

Section: Discussionmentioning

confidence: 99%

Spontaneous remission of a pulmonary sclerosing epithelioid fibrosarcoma: a case report of a possible abscopal effect

Campos Ramírez,

Gómez Mateo,

Ruffini Egea

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

Background Spontaneous remission (SR) is defined as the complete or partial disappearance of a diagnosed malignant disease in the absence of known active medical treatment. The role of the immune system is thought to be important, but has not yet been elucidated. On this matter, there are studies that suggest that the abscopal effect (AE), which is defined as the remission of untreated lesions beyond the irradiated area, may be explained by the activation of a systemic immune response against the tumor. Sclerosing epithelioid fibrosarcoma (SEF) is a rare variant of soft tissue sarcoma that is characterized by a slow evolution, with local recurrences and late metastases. The treatment is based on surgery, leaving a minimal role to chemotherapy (ChT) and radiotherapy (RT) for metastatic unresectable disease, and no cases of SR have been reported in the literature so far. Case Description We present the case of a patient with a lung metastatic recurrence of SEF, diagnosed and treated with surgery 8 years before. After progression to pazopanib and other ChT drugs, because of the chest pain associated with a pleural mass invading the second costal arch, the patient received antalgic local RT treatment. Months later, and without any further treatment, a partial remission of all the tumoral lesions was presented, and she is alive 25 years after the first diagnosis. Conclusions As far as reported in the literature, this is the first case of SR in SEF. Among the possible causes of this SR, we think that the most plausible is that palliative treatment with RT of the pleural mass induced an AE, leading to a reduction of all tumoral lesions, even those outside the irradiated region.

show abstract

SARS-CoV-2-induced remission of advanced classical Hodgkin lymphoma

Cited by 3 publications

References 0 publications

Inactivated SARS-CoV-2 Reprograms the Tumor Immune Microenvironment and Improves Murine Cancer Outcomes

Inactivated SARS-CoV-2 Reprograms the Tumor Immune Microenvironment and Improves Murine Cancer Outcomes

Tumor reduction after SARS‑CoV‑2 infection in a patient with lung cancer: A case report

Spontaneous remission of a pulmonary sclerosing epithelioid fibrosarcoma: a case report of a possible abscopal effect

Contact Info

Product

Resources

About